30-Second Takeaway
- In NSCLC treated with ICIs, antibiotic exposure correlates with worse survival but likely reflects confounding, not a uniform drug–microbiome interaction.
- PD-L1–positive LA HNSCC patients derive PFS benefit from ICIs, while PD-L1–negative patients may be harmed.
- CPOE MDRO-risk prompts reduced extended-spectrum antibiotic use in non-critically ill cancer inpatients without worsening safety.
Week ending June 13, 2026
Five recent oncology studies affecting antimicrobial stewardship, trial representation, and ICI use by biomarker
Antibiotics associated with worse OS/PFS in NSCLC ICI cohorts, but evidence likely confounded
Meta-analysis of 41 studies (n=54,250; 27.8% antibiotic-exposed) found antibiotic exposure associated with worse OS (HR 1.47) and PFS (HR 1.32). No association was seen for objective response rate, and RCT post-hoc estimates were non-significant. Heterogeneity was high and driven by study design and line of therapy, with very low GRADE certainty for observational estimates. The authors conclude the observational signal is more compatible with confounding and exposure heterogeneity than a uniform pharmacologic interaction.
Breast cancer patients accept faster approvals when alternatives lack or benefits are transformative
Qualitative interviews of 30 breast cancer patients explored trade-offs between faster FDA approval and evidentiary uncertainty. Participants most accepted faster approval when no alternatives existed or potential benefits were transformative. Survival and quality of life were prioritized over surrogate endpoints, and patients preferred broader trial access to generate evidence. Views emphasize informed discussion about uncertain benefits before pursuing accelerated-access drugs.
Women remain underrepresented in lung cancer RCTs; female enrollment links to AE reporting
Systematic review of 636 RCTs (n=265,989) found pooled female enrolment disparity of -3.17%, indicating persistent underrepresentation of women. Underrepresentation was pronounced in very high HDI regions and in certain age, race, and stage subgroups. Trial-level differences in female enrolment correlated with differences in reported adverse event incidence. Authors recommend more inclusive recruitment and transparent, sex-disaggregated safety reporting to improve generalisability.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.